Shantsila E et al (2020) Spironolactone in atrial fibrillation with preserved cardiac fraction: the IMPRESS-AF trial, (in eng)
Different tolerability issues: Both can cause gastrointestinal symptoms, but the risk patterns differ
The trials will provide data on the potential disease-modifying effects of semaglutide and will be important in evaluating its utility in the treatment of early-stage symptomatic AD
Details As the publication indicates, previous studies have shown that "people receiving a standard weekly injection of the drug "Wegovy", which contains the active ingredient semaglutide, typically lose about 15% of their body weight within a year in combination with exercise and a healthy diet." The drug works by mimicking the action of the hormone glucagon-like peptide-1, or GLP1, which causes delayed gastric emptying and affects the brain, reducing appetite
Search dates: February 24, 2012, and October 2013.
Christine is a seasoned therapist with over fifteen years of dedicated experience in helping individuals, families, and children navigate life's challenges